Aller au contenu principal
Profil bibliographique

Michał Tkaczyszyn

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

67Publications signalées
1019Citations signalées
3Affiliations récentes

Les institutions déclarées

Les domaines associés

Heart Failure Treatment and ManagementErythropoietin and Anemia TreatmentIron Metabolism and DisordersCardiovascular Function and Risk FactorsCardiovascular and exercise physiology

Les publications récentes

Accès ouvert 2026 article OpenAlex

Circulating metabolomic and lipidomic profiles distinguish patients with acute heart failure de novo vs. worsening of heart failure

Michał Tkaczyszyn, Mateusz Guzik, Gracjan Iwanek, Robert Zymliński et autres

INTRODUCTION: We hypothesized that de novo acute heart failure (AHF) and worsening of pre-existing HF (WHF) reflect distinct underlying metabolic states. OBJECTIVES: Our aim was to compare the circulating metabolomic and lipidomic profiles in de novo AHF and WHF. PATIENTS AND METHODS: …

pl (code pays fourni par la source)

0 citations Polskie Archiwum Medycyny Wewnętrznej
2026 article OpenAlex

Nutritional status and body composition in patients with Fabry disease in comparison to hypertrophic cardiomyopathy

Krzysztof Michał Górniak, W H Lis, Michał Tkaczyszyn, Krzysztof Aleksandrowicz et autres

Abstract Introduction Fabry disease is a systemic disorder that not only leads to left ventricular hypertrophy but also affects many other organs. One of these manifestations may be malnutrition, which would represent a potential therapeutic target. Purpose The aim of this study …

pl (code pays fourni par la source)

0 citations European Journal of Heart Failure
Accès ouvert 2026 article OpenAlex

Landmark clinical trials shaping contemporary guideline-directed medical therapy for heart failure

Michał Tkaczyszyn, Agnieszka Kapłon-Cieślicka, Maciej Janiszewski, Dominika Klimczak‐Tomaniak et autres

Heart failure (HF) management has evolved substantially over recent decades, transitioning from predominantly symptomatic treatment to a strategy grounded in disease-modifying therapies that improve survival and reduce hospitalizations. This review provides a structured and clinically oriented synthesis of landmark randomized controlled trials …

pl, de, ro, fr, es, ca, it (code pays fourni par la source)

0 citations ESC Heart Failure
Accès ouvert 2026 article OpenAlex

Factors associated with quality of life in patients with heart failure and its impact on mortality

Adrian Bednarek, Zuzanna Wojdyńska, Katarzyna Byczkowska, I Kowalik et autres

BACKGROUND: In heart failure (HF), patients' quality of life (QoL) is influenced not only by cardiacfunction but also by coexisting conditions. Despite the widespread use of QoL assessments, therole of patient-related factors as determinants of QoL remains not fully elucidated. AIMS: This …

pl (code pays fourni par la source)

1 citation Kardiologia Polska
Accès ouvert 2026 article OpenAlex

Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry

Maciej T. Wybraniec, Artur Sufryd, Małgorzata Cichoń, Tomasz Tokarek et autres

AIMS: Cardiogenic shock (CS) represents an ominous complication of acute myocardial infarction (AMI) with a mortality rate exceeding 50%. The aim of the study was to evaluate current management, outcomes, and risk factors of mortality of AMI-related CS. METHODS: This snapshot registry …

pl, nl, gb (code pays fourni par la source)

0 citations ESC Heart Failure
Accès ouvert 2026 article OpenAlex

Transthyretin amyloid cardiomyopathy—new data regarding epidemiology, diagnosis, and treatment

Michał Tkaczyszyn

The growing awareness of cardiologists regarding amyloid transthyretin cardiomyopathy (ATTR-CM), together with increasingly precise non-invasive diagnostic approaches—particularly the development of practical diagnostic algorithms that streamline and facilitate the interpretation of parallel nuclear medicine and haematology tests—and finally, the dynamic progress of targeted …

pl (code pays fourni par la source)

0 citations ESC Heart Failure
Accès ouvert 2026 article OpenAlex

Contemporary heart failure evidence in 2025: a joint summary of key trials from the European Journal of Heart Failure and ESC Heart Failure Journal

Jan Biegus, Antoni Bayés‐Genís, Stephan von Haehling, Wojciech Kosmala et autres

Heart failure (HF) remains a major global health challenge, characterized by high morbidity, mortality, and healthcare costs despite substantial advances in pharmacological, device-based, and structural therapies. Its increasing prevalence reflects population ageing, improved survival after myocardial infarction, and the rising burden of …

pl, es, de, hu, se (code pays fourni par la source)

1 citation European Journal of Heart Failure
Accès ouvert 2025 article OpenAlex

From underrecognition to structured care: ATTR cardiac amyloidosis in Poland. Insights from a multicenter national cohort

Carsten Tschöpe, Michał Tkaczyszyn

For many years, transthyretin cardiac amyloidosis (ATTR-CM) lived in the blind spot of routine cardiology [1].Across Europe, patients with heart failure with preserved ejection fraction (HFpEF), unexplained left ventricular wall thickening, atrial arrhythmia, or low-flow aortic stenosis were often managed symptomatically long …

de, pl (code pays fourni par la source)

1 citation Kardiologia Polska
2025 article OpenAlex

High-dose guideline-directed medical therapy at discharge reduces mortality in hospitalized patients with heart failure with reduced ejection fraction: evidence from the HEROES study

Paweł Krzesiński, A A Galas, Robert Morawiec, M Grabowski et autres

Abstract Introduction Guideline-directed medical therapy (GDMT) is recommended in patients with heart failure and reduced ejection fraction (HFrEF) to reduce hospitalizations and mortality. Every medical contact, including hospitalization, should be used to initiate or up-titrate GDMT. However, still only a few patients …

us, pl (code pays fourni par la source)

0 citations European Heart Journal
2025 article OpenAlex

Heart failure with supranormal ejection fraction as a new HF phenotype. Clinical profile and prognosis of patients with based on the Heart Failure Observational Study of the Polish Cardiac Society

Robert Morawiec, Paweł Maeser, Maciej Nadel, Agata Anna Galas et autres

Abstract Over recent years, heart failure (HF) with supranormal ejection fraction (snEF) has been postulated as a distinct phenotype of heart failure. It has been proven that patients with snEF (defined as EF ≥60% or ≥65%, depending on the analysis) have a …

pl, us (code pays fourni par la source)

0 citations European Heart Journal
2025 article OpenAlex

Factors influencing the quality of life in patients with heart failure and its impact on mortality: insights from HEROES registry

Adrian Bednarek, Zuzanna Wojdyńska, Katarzyna Byczkowska, I Kowalik et autres

Abstract Background Novel therapies for heart failure (HF) are introduced not only to prevent clinical events but also to improve patients' quality of life (QoL). HF patients often present with multiple non-cardiac comorbidities, which may impact their prognosis and patient-reported outcomes. Despite …

pl, us (code pays fourni par la source)

0 citations European Heart Journal
2025 article OpenAlex

Heart rate control in heart failure: insights from nationwide multicenter registry HEROES

Jaroslaw D Kasprzak, Robert Morawiec, Agata Anna Galas, Agata Tymińska et autres

Abstract Aim HEart failuRe ObsErvational Study of the Polish Cardiac Society (HEROES) is a prospective, multi-center, observational all-comers study aimed to assess clinical profile of heart failure (HF) pts (patients) in a representative national sample (41 centers). This analysis reports aspects of …

pl, us (code pays fourni par la source)

0 citations European Heart Journal

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.